Your browser doesn't support javascript.
loading
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti, Abhishek; DiNardo, Courtney D; Qiao, Wei; Kadia, Tapan M; Jabbour, Elias J; Rausch, Caitlin R; Daver, Naval G; Short, Nicholas J; Borthakur, Gautam; Pemmaraju, Naveen; Yilmaz, Musa; Alvarado, Yesid; Montalbano, Kathryn S; Wade, Allison; Maduike, Rita E; Guerrero, Julio A; Vaughan, Kenneth; Bivins, Carol A; Pierce, Sherry; Ning, Jing; Ravandi, Farhad; Kantarjian, Hagop M; Konopleva, Marina Y.
Afiliação
  • Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rausch CR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Montalbano KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wade A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maduike RE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Guerrero JA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vaughan K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bivins CA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 127(22): 4213-4220, 2021 11 15.
Article em En | MEDLINE | ID: mdl-34343352
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Limite: Adult / Humans Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Limite: Adult / Humans Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article